Opus Genetics/$IRD

1D1W1MYTD1Y5YMAX

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Ticker
$IRD
Sector
Health
Primary listing
NASDAQ
Employees
28
Headquarters
Durham, United States
Website
opusgtx.com

Opus Genetics Metrics

BasicAdvanced
$431M
-
-$1.29
0.58
-

What the Analysts think about Opus Genetics

Analyst ratings (Buy, Hold, Sell) for Opus Genetics stock.
Analyst projections of the future price of Opus Genetics stock.

Bulls say / Bears say

OPGx-BEST1 produced positive early proof-of-concept data: all five Cohort 1 participants showed clinically meaningful visual-function improvement, four showed structural improvement, and no serious adverse events or dose-limiting toxicities were observed. (Opus Genetics)
Opus completed enrollment in the registrational OPGx-LCA5 Phase 3 trial after FDA alignment on the design, with dosing expected to begin in Q4 2026. The program could support a relatively near-term regulatory catalyst in an ultra-rare disease with no established genetic treatment. (Opus Genetics)
The company reported cash and cash equivalents of $88.8 million at June 30, 2026 and expects available resources to fund operations into 2029, supporting multiple clinical programs and upcoming inflection points across LCA5, BEST1, RDH12, MERTK and RHO. (Opus Genetics)
OPGx-BEST1’s encouraging results are based on only five participants in an open-label Phase 1/2 cohort, with interim data that the company says may change materially as follow-up continues; efficacy therefore remains unproven in a controlled pivotal setting. (Opus Genetics)
Opus remains loss-making and noncommercial: Q2 2026 revenue was only $0.8 million, while R&D expense rose to $11.2 million and the quarterly net loss was $8.1 million. Continued clinical expansion will require substantial spending before any product revenue is generated. (Opus Genetics)
The financing plan reduces near-term liquidity risk but adds execution and capital-structure risk: the Oberland facility is secured, bears interest, and much of the potential $155 million is conditional on future funding conditions or milestones; the company also issued $5 million of equity. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

Opus Genetics Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Opus Genetics Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Opus Genetics

Funds
Fund name
Fund size
$IRD weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.